Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

• Status: Completed
• Trial end date: 2007-07-01

Summary

To determine the long-term safety and efficacy of a dose range of safinamide of 50-200 mg/day, p.o., compared to placebo, as add-on therapy in patients with early idiopathic Parkinson's disease who are currently receiving a stable dose of a single dopamine (DA) agonist.

• Phase: Phase 3

Details

• Lead Sponsor: Newron; Newron Pharmaceuticals SPA
• Treatments: Dopamine; Dopamine Agonists